r-chop versus r-bendamustine in fl
Published 2 years ago • 173 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
1:44
remodl-b: bortezomib r-chop versus r-chop in patients with dlbcl
-
2:15
frontmind: tafasitamab lenalidomide r-chop vs r-chop for newly diagnosed high-risk dlbcl
-
2:20
frontmind: tafasitamab lenalidomide r-chop vs r-chop in newly diagnosed high-risk dlbcl
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl
-
6:35
high grade diffuse large b-cell lymphoma: carole's story
-
1:46
r-chop versus r-bendamustine in fl
-
10:07
understanding diffuse large b-cell lymphoma with bruce cheson, md, facp, faaas, fasco
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
1:23
findings from the ro-chop trial in patients with r/r ptcl
-
1:09
assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with b-cell malignancies
-
1:00
phase ib trial of r-chop plus iberdomide or cc-99282 in aggressive b-cell lymphoma
-
3:53
frontmind: tafasitamab lenalidomide r-chop vs r-chop in high-intermediate & high-risk dlbcl
-
1:27
atezolizumab plus r-chop in dlbcl: encouraging results
-
5:30
how the treatment landscape of dlbcl is changing: r-chop vs pola-r-chp
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
6:12
coalition: glofitamab r-chop or glofitamab pola-r-chp in patients with high-risk dlbcl
-
1:57
r-chop dose intensity and survival outcomes in dlbcl
-
1:28
first-mind: phase ib study of r-chop tafasitamab ± lenalidomide in newly diagnosed dlcbl
-
4:16
glofitamab plus r-chop in patients with high-risk lbcl: a phase ii trial
-
1:23
phoenix: ibrutinib in combination with r-chop for dlbcl
-
1:12
smart stop: moving away from r-chop in dlbcl